SMS Pharmaceuticals Reports 29% PAT Growth YoY in Q3FY26, Driven by Volume Growth and Operating Leverage

SMS Pharmaceuticals, a diversified and integrated pharmaceutical company, has reported a 21% YoY increase in revenue from operations for Q3FY26, supported by strong demand, volume ramp-up in key products, and market share gains across key APIs. The company's gross margins improved to 35.59% due to the full-quarter impact of the backward integration project commissioned in Q1 FY26. EBITDA margins for Q3FY26 stood at 20.74%, while PAT margins rose to 11.15%. The X280 crore capacity expansion programme is progressing as planned and is expected to enhance capacity for existing APIs, build capacity for new product pipeline, expand R&D capabilities, and enable upcoming growth initiatives. The company remains confident of delivering ~20% revenue growth in FY26 with EBITDA margins above 20%.